{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:30:53Z","timestamp":1761183053460,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jiac.2021.06.004","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T08:59:17Z","timestamp":1625216357000},"page":"1436-1446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The safety and efficacy of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate for Inhalation Suspension Set in children under the age of 5 in a post-marketing surveillance"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2995-402X","authenticated-orcid":false,"given":"Takashi","family":"Nakano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Shiosakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Chikada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yomei","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2021.06.004_bib1","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1086\/656802","article-title":"Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, moninferiority clinical trial","volume":"51","author":"Watanabe","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2021.06.004_bib2","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1128\/AAC.01755-09","article-title":"Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection","volume":"54","author":"Sugaya","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2021.06.004_bib3","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1007\/s10156-013-0622-9","article-title":"Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial","volume":"19","author":"Kashiwagi","year":"2013","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2021.06.004_bib4","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/cid\/ciw255","article-title":"Long-acting neuraminidase inhibitor laninamivir octanoate as post-exposure prophylaxis for influenza","volume":"63","author":"Kashiwagi","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2021.06.004_bib5","unstructured":"Inavir Dry powder inhaler pharmaceutical interview form revised in september 2020 (fourteenth ed.) [in Japanese]."},{"key":"10.1016\/j.jiac.2021.06.004_bib7","first-page":"573","article-title":"Administration setting and status of inhalation of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate in post-marketing surveillance","volume":"60","author":"Kashiwagi","year":"2012","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.jiac.2021.06.004_bib8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jiac.2018.04.009","article-title":"In vitro neuraminidase inhibitory concentration (IC50) of four neuraminidase inhibitors in the Japanese 2016-17 season: comparison with the 2010-2011 to 2015-2016 seasons","volume":"24","author":"Ikematsu","year":"2018","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2021.06.004_bib9","unstructured":"Inavir for Inhalation Suspension Set. Pharmaceutical interview form revised october 2019 (third ed.) [in Japanese]."},{"key":"10.1016\/j.jiac.2021.06.004_bib10","first-page":"1123","article-title":"Estimation of the incidence of febrile convulsion in influenza","volume":"104","author":"Katayose","year":"2000","journal-title":"J Jpn Pediatr Soc"},{"key":"10.1016\/j.jiac.2021.06.004_bib11","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ijantimicag.2012.06.017","article-title":"Safety of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate in post-marketing surveillance","volume":"40","author":"Kashiwagi","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2021.06.004_bib12","first-page":"21","article-title":"Analysis of influenza in the winter 2004\/2005. Comparison between type A and Type B","volume":"4252","author":"Kawai","year":"2005","journal-title":"Nihon Iji Shinpo"},{"key":"10.1016\/j.jiac.2021.06.004_bib13","first-page":"41","article-title":"Analysis of influenza in the winter 2004\/2005. Comparison between type A and Type B with respect to fever and efficacy of oseltamivir","volume":"7","author":"Kawai","year":"2006","journal-title":"Influenza"},{"key":"10.1016\/j.jiac.2021.06.004_bib14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1086\/505868","article-title":"A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons","volume":"43","author":"Kawai","year":"2006","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X21001653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X21001653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:02:55Z","timestamp":1761159775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X21001653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1341321X21001653"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2021.06.004","relation":{},"ISSN":["1341-321X"],"issn-type":[{"type":"print","value":"1341-321X"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The safety and efficacy of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate for Inhalation Suspension Set in children under the age of 5 in a post-marketing surveillance","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2021.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}